Elemento

FDA to create training program to inspect more mRNA vaccine manufacturing

Título (Dublin Core)

FDA to create training program to inspect more mRNA vaccine manufacturing

Description (Dublin Core)

This is a news story from Endpoints News by Josh Sullivan. With new faith being poured into mRNA vaccines, a new training program is being developed to help with the manufacturing process. This program will entail learning the application of mRNA vaccines, as well as laboratory training.

BioNTech, Pfizer’s partner in its Covid-19 vaccine efforts, recently revealed that it is paying Matinas BioPharma to gain exclusive access to its lipid nanocrystal drug delivery platform for the oral delivery of mRNA. It also was one of the first companies to announce plans for the massive mRNA manufacturing sites that are being built. BioNTech plans to piggyback off the success of the technology by pivoting to work on malaria vaccines once the Covid-19 pandemic has subsided.

Date (Dublin Core)

May 5, 2022

Creator (Dublin Core)

Josh Sullivan

Event Identifier (Dublin Core)

HST580

Partner (Dublin Core)

Arizona State University

Tipo (Dublin Core)

Text story

Link (Bibliographic Ontology)

Controlled Vocabulary (Dublin Core)

English Healthcare
English News coverage
English Science

Curator's Tags (Omeka Classic)

mRNA
Vaccine
FDA
Science

Contributor's Tags (a true folksonomy) (Friend of a Friend)

mRNA
vaccine
FDA
BioNTech
manufacturing
training
science

Collection (Dublin Core)

Healthcare
Vaccine Stories

Linked Data (Dublin Core)

Date Submitted (Dublin Core)

05/05/2022

Date Modified (Dublin Core)

05/07/2022
07/09/2022
08/02/2022

Date Created (Dublin Core)

05/05/2022

Colecciones

This item was submitted on May 5, 2022 by [anonymous user] using the form “Share Your Story” on the site “A Journal of the Plague Year”: https://covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA